

Maine Naloxone Distribution Initiative

Project-To-Date Totals through September 30, 2025

Prepared by the Margaret Chase Smith Policy Center
University of Maine

In July 2019, the Maine Naloxone Distribution Initiative (MNDI) launched an overdose education, prevention, and naloxone distribution project. Public health and harm reduction partners, known as Tier 1 Distributors, began distributing state-supplied naloxone rescue kits across Maine to clinicians, community partners, and end users. This brief provides information on naloxone distribution and reported overdose reversals by the Tier 1 organizations comprising the MNDI from the initiation of the project through September 2025, with a particular emphasis on the third quarter of 2025. Additionally, subcategories of naloxone distribution from Tier 1 organizations to the Overdose Prevention Through Intensive Outreach Naloxone and Safety (OPTIONS) initiative and syringe services/access programs in 2021 as well as EMS Naloxone Leave Behind Program are provided.

Tier 1 organizations include Bangor Public Health (BPH), Portland Public Health (PPH), MaineGeneral Health (MG), and Maine Access Points (MAP). BPH serves the Aroostook, Downeast, and Penquis public health districts, PPH serves Cumberland and York, and MG serves Central, Midcoast, and Western. MAP distributes naloxone statewide with a particular focus on rural regions. Data from the Office of the Attorney General's (OAG) law enforcement administered naloxone program have also been included to provide an overview of the combined public health, harm reduction, and public safety efforts in Maine.

Currently, it is hard to measure the effectiveness of naloxone distribution because the total number of overdose reversals relies on voluntary reporting. The distribution and reported reversal data tables and figure in this report offer conservative estimates of the lives saved through public health, harm reduction, and safety efforts, which prevented the number of drug deaths from potentially being much higher.

Monthly proportions of 2025 fatalities from January to September averaged 4.9%, moderately lower than the 5.7% in 2024 and the 6.1% in 2023. Monthly proportions in 2025 ranged from a high of 6.1% in February to a low of 4.1% in May.¹

¹ (Sorg et al. 2025). Additional resources, data, and visualizations are available at the Maine Drug Data Hub: <https://mainedrugdata.org/>.




Figure 1: County-level naloxone distribution levels per 100 residents (with point of initial township distribution indicated by star) by the Maine Naloxone Distribution Initiative from July through September 2025.

Note: BPH naloxone purchase and distribution has been delayed Jul–Sep 2025 due to pending contracting delays, which has decreased naloxone distribution for the northern sector of the state.

Public Health—Tier 1 Distributors

During the third quarter of 2025 (July–September):

28,420 doses of naloxone have been distributed
264 overdose reversals have been voluntarily reported.

From July 2019 through September 2025 (MNDI project-to-date totals):

738,008 doses of naloxone have been distributed
9,984 overdose reversals have been voluntarily reported.

Public Safety—Law Enforcement Agencies

During the third quarter of 2025 (July–September):

404 doses of naloxone have been distributed
16 overdose reversals have been voluntarily reported.

From July 2019 through September 2025:

23,012 doses of naloxone have been distributed
1,892 overdose reversals have been voluntarily reported.

Table 1 Doses of naloxone distributed by Tier 1 distributors and OAG

| | 2019– 2023 | 2024 | Jan–Mar 2025 | Apr–Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Total |
|----------|---------------|--------|-----------------|-----------------|-------------|-------------|-------------|--------|
| BPH (IN) | 96692 | 43628 | 3612 | 31332 | 8 | 84 | 38 | 175394 |
| BPH (RI) | 0 | 4416 | 48 | 4104 | 0 | 0 | 0 | 8568 |
| BPH (IM) | 0 | 0 | 0 | 13300 | 0 | 0 | 0 | 13300 |
| PPH (IN) | 83639 | 36706 | 6260 | 9266 | 2078 | 3238 | 2656 | 143843 |
| PPH (IM) | 1714 | 1934 | 500 | 844 | 214 | 50 | 150 | 5406 |
| PPH (RI) | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 4 |
| MG | 76354 | 34888 | 8206 | 16450 | 1954 | 4014 | 4512 | 146378 |
| MAP (IM) | 146481 | 16654 | 5440 | 3424 | 1180 | 1862 | 1978 | 177019 |
| MAP (IN) | 35738 | 14698 | 1450 | 318 | 0 | 0 | 0 | 52204 |
| MAP (RI) | 0 | 2454 | 4858 | 4180 | 1086 | 2012 | 1302 | 15892 |
| OAG | 18324 | 3180 | 420 | 684 | 192 | 64 | 148 | 23012 |
| Total | 458942 | 158558 | 30794 | 83902 | 6712 | 11328 | 10784 | 761020 |

Notes: (1) Unit is doses for all values. (2) IM = intramuscular; IN = intranasal; RI = RiVive®. All values are IN unless otherwise indicated. (3) MAP distribution initially included state-supplied and nonstate-supplied naloxone. (4) 2019 data is for July through December only. (5) A revision has been made to BPH January and July, 2020 and March 2021 and PPH April 2021, Jan 2022 and MG March 2020, October, November, December 2021 and March, April 2022. OBH 2019, 2020, 2021 and 2022. (5) Table 1 includes corrections for MAP reporting that include a decrease in IN doses and an increase in IM doses. 1957 doses of IN naloxone were removed from distribution data from 07/2019 to 07/2023 and 13926 doses of IM naloxone were added to distribution data from 07/2019 to 07/2023. (6) Beginning June of 2024, the MNDI will be purchasing and distributing lower dose (3mg) naloxone (RiVive®). (7) BPH naloxone purchase and distribution has been delayed Jul–Sep 2025 due to pending contracting delays.

Table 1.1 Doses of naloxone distributed by Tier 1 distributors to OPTIONS liaisons (subcategory of total distribution)

| | 2021– 2023 | 2024 | Jan– Mar 2025 | Apr– Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Total |
|-------|---------------|-------|---------------------|---------------------|-------------|-------------|-------------|-------|
| BPH | 7012 | 5326 | 768 | 6376 | 0 | 0 | 0 | 19482 |
| PPH | 4150 | 2548 | 728 | 816 | 0 | 792 | 744 | 9778 |
| MG | 9292 | 4720 | 1416 | 1128 | 192 | 552 | 264 | 17564 |
| Total | 20454 | 12594 | 2912 | 8320 | 192 | 1344 | 1008 | 46824 |

Notes: (1) Unit is doses for all values.

Table 1.2 Doses of naloxone distributed by Tier 1 distributors through syringe services/ access programs (subcategory of total distribution)

| | 2021– 2023 | 2024 | Jan– Mar 2025 | Apr– Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Total |
|-------|---------------|-------|---------------------|---------------------|-------------|-------------|-------------|--------|
| BPH | 20034 | 9764 | 456 | 22364 | 0 | 0 | 0 | 52618 |
| PPH | 25511 | 9536 | 2486 | 3798 | 718 | 508 | 792 | 43349 |
| MG | 8120 | 2836 | 344 | 438 | 216 | 92 | 166 | 12212 |
| MAP | 97894 | 32596 | 11476 | 7986 | 2096 | 3120 | 2956 | 158124 |
| Total | 151559 | 54732 | 14762 | 34586 | 3030 | 3720 | 3914 | 266303 |

Notes: (1) Unit is doses for all values. (2) A revision has been made to BPH March, June, September of 2021 January, April and May of 2022 as well as PPH April 2021 and February of 2023. (3) Missing data for January 2021 for PPH.

Table 1.3 Doses of naloxone distributed by Tier 1 distributors to EMS Naloxone Leave Behind Program (subcategory of total distribution)

| | 2022– 2023 | 2024 | Jan– Mar 2025 | Apr– Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Total |
|-------|---------------|------|---------------------|---------------------|-------------|-------------|-------------|-------|
| BPH | 1628 | 884 | 142 | 274 | 8 | 84 | 38 | 3058 |
| PPH | 1228 | 510 | 70 | 250 | 32 | 40 | 76 | 2206 |
| MG | 2022 | 1308 | 210 | 246 | 174 | 312 | 266 | 4538 |
| Total | 4878 | 2702 | 422 | 770 | 214 | 436 | 380 | 9802 |

Notes: (1) Unit is doses for all values. (2) The EMS Leave Behind Program was launched in January of 2022. TIs are to provide EMS agencies across the state with kits of naloxone to provide to anyone who has refused EMS transport.

Table 2 Number of overdose reversals voluntarily reported to Tier 1 distributors (by individuals or Tier 2 distributors) and overdose reversals reported by OAG law enforcement agencies through the reporting tool called ODMAP

| | 2019– 2023 | 2024 | Jan–Mar 2025 | Apr–Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Total |
|-----------|---------------|------|-----------------|-----------------|----------|-------------|-------------|-------|
| BPH | 2382 | 551 | 68 | 153 | 34 | 40 | 26 | 3254 |
| PPH | 1344 | 402 | 51 | 52 | 10 | 16 | 17 | 1892 |
| MG | 836 | 216 | 32 | 26 | 7 | 6 | 3 | 1126 |
| MAP | 3063 | 362 | 47 | 43 | 18 | 14 | 68 | 3615 |
| OAG | 1703 | 130 | 15 | 28 | 3 | 8 | 5 | 1892 |
| OD-ME app | 77 | 14 | 1 | 0 | 1 | 0 | 4 | 97 |
| Total | 9405 | 1675 | 214 | 302 | 73 | 84 | 123 | 11876 |

Notes: (1) Reversal totals are conservative estimates as not all reversals are reported. (2) OD-ME app is a mobile phone app developed in 2020 to support naloxone administration. (3) Overdose reversal figures may increase as backdated Tier 2 distributor and OAG incident reports are received. (4) 2019 data is July through December only. (5) Law enforcement agencies that receive naloxone from the OAG and report reversals through ODMAP are now being included. ODMAP reversal data has been added from July 2019 to present. (6) A revision has been made to MAP 2022 and PPH February 2023 reversal reports as well as OAG Q1 2023